Reported associations include vaccinations (hepatitis B, COVID-19), pharmacological agents, such as interferon-alpha and ribavirin for hepatitis C, immune checkpoint inhibitors (nivolumab), and BRAF/MEK inhibitors (encorafenib and binimetinib) [7-12]. This evidence concerns the gene MAP2K7 and hepatitis C virus infection.